DARE BIOSCIENCE INC (DARE) Stock Price, Forecast & Analysis
NASDAQ:DARE • US23666P2002
DARE Key Statistics, Chart & Performance
The current stock price of DARE is 1.66 USD. In the past month the price decreased by -14.87%. In the past year, price decreased by -47.13%.
DARE Technical Analysis
DARE Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to DARE. DARE has a bad profitability rating. Also its financial health evaluation is rather negative.
DARE Financial Highlights
Over the last trailing twelve months DARE reported a non-GAAP Earnings per Share(EPS) of -1.88. The EPS decreased by -218.64% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -13.18% | ||
| ROE | -141.84% | ||
| Debt/Equity | 1.88 |
DARE Forecast & Estimates
10 analysts have analysed DARE and the average price target is 10.97 USD. This implies a price increase of 560.54% is expected in the next year compared to the current price of 1.66.
For the next year, analysts expect an EPS growth of -223.65% and a revenue growth -72.64% for DARE
DARE Ownership
DARE Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 31.05 | 1.001T | ||
| JNJ | JOHNSON & JOHNSON | 21.14 | 592.302B | ||
| MRK | MERCK & CO. INC. | 22.9 | 307.324B | ||
| PFE | PFIZER INC | 9.04 | 153.855B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 10.12 | 124.69B | ||
| ZTS | ZOETIS INC | 18.73 | 55.434B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.75 | 26.247B | ||
| VTRS | VIATRIS INC | 6.35 | 18.371B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 25.23 | 12.297B | ||
| AXSM | AXSOME THERAPEUTICS INC | 213.7 | 8.81B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About DARE
Company Profile
Daré Bioscience, Inc. operates as a healthcare company, which engages in the development and commercialization of pharmaceutical products in women's reproductive health. The company is headquartered in San Diego, California and currently employs 21 full-time employees. The company went IPO on 2014-04-10. The firm's programs target unmet needs in women's health, primarily in the areas of contraception, sexual health, pelvic pain, fertility, infectious disease, vaginal health and menopause. Its product includes XACIATO (clindamycin phosphate) vaginal gel 2%. XACIATO is a single-dose prescription medication for the treatment of bacterial vaginosis in females 12 years of age and older. Its other product candidates include Ovaprene, Sildenafil Cream, and DARE-HRT1. Ovaprene is an investigational, hormone-free, monthly intravaginal contraceptive. Sildenafil Cream is a novel cream formulation of sildenafil for the treatment of female sexual arousal disorder; and DARE-HRT1 is an intravaginal ring designed to deliver a combination of menopausal hormone therapy, bio-identical 17b-estradiol and progesterone together, continuously over a 28-day period for the treatment of moderate to severe vasomotor symptoms, also known as hot flashes.
Company Info
DARE BIOSCIENCE INC
3655 Nobel Dr Ste 260
San Diego CALIFORNIA 92122 US
CEO: Sabrina Martucci Johnson
Employees: 22
Phone: 18589267655
DARE BIOSCIENCE INC / DARE FAQ
Can you describe the business of DARE BIOSCIENCE INC?
Daré Bioscience, Inc. operates as a healthcare company, which engages in the development and commercialization of pharmaceutical products in women's reproductive health. The company is headquartered in San Diego, California and currently employs 21 full-time employees. The company went IPO on 2014-04-10. The firm's programs target unmet needs in women's health, primarily in the areas of contraception, sexual health, pelvic pain, fertility, infectious disease, vaginal health and menopause. Its product includes XACIATO (clindamycin phosphate) vaginal gel 2%. XACIATO is a single-dose prescription medication for the treatment of bacterial vaginosis in females 12 years of age and older. Its other product candidates include Ovaprene, Sildenafil Cream, and DARE-HRT1. Ovaprene is an investigational, hormone-free, monthly intravaginal contraceptive. Sildenafil Cream is a novel cream formulation of sildenafil for the treatment of female sexual arousal disorder; and DARE-HRT1 is an intravaginal ring designed to deliver a combination of menopausal hormone therapy, bio-identical 17b-estradiol and progesterone together, continuously over a 28-day period for the treatment of moderate to severe vasomotor symptoms, also known as hot flashes.
Can you provide the latest stock price for DARE BIOSCIENCE INC?
The current stock price of DARE is 1.66 USD.
Does DARE BIOSCIENCE INC pay dividends?
DARE does not pay a dividend.
How is the ChartMill rating for DARE BIOSCIENCE INC?
DARE has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Can you provide the number of employees for DARE BIOSCIENCE INC?
DARE BIOSCIENCE INC (DARE) currently has 22 employees.
Can you provide the ownership details for DARE stock?
You can find the ownership structure of DARE BIOSCIENCE INC (DARE) on the Ownership tab.
What is the Short Interest ratio of DARE BIOSCIENCE INC (DARE) stock?
The outstanding short interest for DARE BIOSCIENCE INC (DARE) is 2.38% of its float.